Allstate Corporation’s NovoCure NVCR Stock Holding History

Allstate Corporation’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$285K	Buy	+18,786	New	+$284K	﹤0.01%	1213
2023 Q1	–	Sell	-3,956	Closed	-$290K	–	451
2022 Q4	$290K	Buy	3,956 +85	+2%	+$6.4K	0.01%	554
2022 Q3	$294K	Sell	3,871 -18	-0.5%	-$1.4K	0.01%	560
2022 Q2	$270K	Sell	3,889 -791	-17%	-$59.6K	0.01%	578
2022 Q1	$388K	Buy	+4,680	New	+$345K	0.01%	540
2021 Q4	–	Sell	-2,979	Closed	-$346K	–	756
2021 Q3	$346K	Buy	2,979 +519	+21%	+$78.5K	0.01%	593
2021 Q2	$546K	Buy	+2,460	New	+$479K	0.02%	500
2021 Q1	–	Sell	-1,195	Closed	-$207K	–	737
2020 Q4	$207K	Buy	+1,195	New	+$164K	0.01%	692

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Allstate Corporation's NVCR Position: Q2 2026 in Review

Allstate Corporation opened a new position in NovoCure (NVCR) in Q2 2026: 18,786 shares worth $285K. The stake represents ﹤0.01% of the portfolio and ranks #1213 among its holdings. This is a return to the name: Allstate Corporation previously reported a position in NVCR as recently as Q4 2022.

Allstate Corporation first reported a position in NVCR in Q4 2020 and has held it in 8 quarters since. The position peaked at $546K in Q2 2021. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Allstate Corporation held 18,786 shares of NovoCure worth $285K as of Q2 2026.
NovoCure was a new Allstate Corporation position in Q2 2026.
NovoCure made up ﹤0.01% of Allstate Corporation's portfolio in Q2 2026, its #1213 holding.
Allstate Corporation first reported a position in NovoCure in Q4 2020 and has held it in 8 quarters since.
Allstate Corporation's NovoCure position peaked at $546K in Q2 2021.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.